Corticosteroids are the commonly used drug therapy for chronic rhinosinusitis with nasal polyps (CRSwNP) after surgery. While topical corticosteroids effectively reduce the symptom associated with CRS and systemic side effects, their distribution inside the nasal cavity is limited and primarily dependent on the release of mediators. Corticosteroid eluting stents serve as a relatively novel technology that can deliver high concentrations of corticosteroids directly and continuously onto the sinus mucosa. At present, drug implant for CRS are most commonly used during and after endoscopic sinus surgery (ESS), which are beneficial to improve mucosal inflammation burden and postoperative symptoms, and reduce the recurrence of nasal polyps. This paper reviews the clinical efficacy and safety evidence of two corticosteroid eluting stents. Drug stents combined with other topical drug administration can give better drug distribution and provide ideas for intraoperative and postoperative combined drug use.